Article Sidebar

Submitted
June 29, 2022
Published
June 30, 2022
Download
PDF
Statistic
Read Counter : 2891 Download : 1

Main Article Content

Abstract

Nifedipine is an anti-hypertensive included in the Biopharmaceutics Classification System (BCS) class II to its nature of being poorly soluble in water, resulting in low bioavailability. One technique that can be used to improve the solubility of the dispersion technique. This research aimed to determine the effect of the concentration of PVP K-30 on physical characteristics, the dissolution rate of solid dispersions, and the interactions that occur between nifedipine with PVP K-30. The method of manufacturing solid dispersion is a melting-solvent method. FI - F III is a solid dispersion and F IV-VI F is a physical mixture. Formula used is the ratio of nifedipine: PVP K-30 FI (10%: 90%), F II (20%: 80%), F III (30%: 70%), F IV (10%: 90%), FV (20%: 80%), F VI (30%: 70%), and used as a control of pure nifedipine. Testing was conducted on the organoleptic test, flow rate, moisture content, melting point, dissolution testing, and FT-IR analysis. Dissolution test parameters used C (20). The data was obtained and analyzed by non-parametric test KruskalWallis and Mann-Whitney with a level of 95%. The results showed that solid dispersions aregranulated, yellow, and have a free-flowing nature. Test results C (20) FI, F II, F III, F IV, FV, F VI, and controls respectively were 89,48%; 51,75%; 22,58%; 12,88%; 24,07%; 26,34%; 24,95%. The results showed that the FI has the highest dissolved. Results of FT-IR spectra showed no interaction between nifedipine with PVP K-30.

 

Keywords

dissolution nifedipine PVP K-30 solid dispersion

Article Details

References

  1. Cai, T., Zhu, L., Yu, L., 2011, Crystallization of Organic Glasses: Effects of Polymer Additives on
  2. Bulk and Surface Crystal Growth in Amorphous Nifedipine, Pharm.Res, 28(10), 2458-66.
  3. Craig, D.Q.M, 2002, The mechanisms of drug release from solid dispersions in water-soluble
  4. polymers, Int J Pharm, 231,131–144.
  5. Firdaus, 2011, Teknik Dalam Laboratorium Kimia Organik, Makasar: Universitas Hasanudin.
  6. Friedrich, H., Nada, A., Bodmeier, R., 2005, Solid state and dissolution rate characterization of co-
  7. ground mixtures of nifedipine and hydrophilic carriers. Drug Dev Ind Pharm, 3, 719–728.
  8. Haware, R.V., Vinjamuri, B.P., Gavireddi, M., Dave, V.S., Gupta, D, Chougule, M.B., Stagner,
  9. W.C., 2019, Physical properties and solubility studies of Nifedipine-PEG 1450/HPMCAS-
  10. HF solid dispersions, Pharm. Dev. Technol, 24(5), 550-559.
  11. He, Y., and Ho, C., 2015, Amorphous Solid Dispersions: Utilization and Challenges in Drug
  12. Discovery and Development, J.Pharm.Sci, 104(10), 3237-3258.
  13. Iqbal, W.S., and Chan, K.L., 2015, FTIR spectroscopic study of poly(ethylene glycol)-nifedipine
  14. dispersion stability in different relative humidities, J.Pharm. Sci, 104 (1), 280-284 .
  15. Kumar, Kiran, M., Chinna, E., and V.N.L, Sirisha, 2012, Solubility Enhancement Techniques Of
  16. Drug, International Research Journal of Pharmaceutical and Applied Sciences, 2(5), 49-55.
  17. Lenz, E., Lobmann, Rades, T., Knop, K., Kleinebuddie, P., 2017, Hot Melt Extrusion and Spray
  18. Drying of Co-amorphous Indomethacin-Arninie with Polymers, J.Pharm.Sci, 106(1), 302-
  20. Leuner, C, and Dressman, J., 2000, Improving drug solubility for oral delivery using solid
  21. dispersions, Eur J Pharm Biopharm, 50,47–60.
  22. Mahale, A.M., and S.A., Sreenivas, 2011, Enhancement Of Dissolution Profile Of Nifedipine By
  23. Solid Dispersion Technique, IJPI’s Journal Of Pharmaceutics And Cosmetology, 1(6), 2.
  24. Marsac, P.J., Konno, H., and Taylor, L.S., 2006, A Comparison of the Physical Stability of
  25. Amorphous Felodipine and Nifedipine System, Pharm Res, 23 (10), 2306-2316.
  26. Marsac, P.J., Konno, H., Rumondor, A.C.F., and Taylor, L.S., 2008, Recrystallization of
  27. Nifedipine and Felodipine from Amorphous Molecular Level Solid Dispersions Containing
  28. Poly(vinylpyrrolidone) and Sorbed Water, Pharm Res, 25 (3), 647-656.